Industry Perspective on Biomarker Development and Qualification.

about

Process Improvement for Maximized Therapeutic Innovation Outcome.

P2860

Q47229510-7A09D829-95D4-4401-B794-B050BA04E985

P2860

Industry Perspective on Biomarker Development and Qualification.

Item

http://www.wikidata.org/entity/Q49969133

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Industry Perspective on Biomarker Development and Qualification.

@en

Industry Perspective on Biomarker Development and Qualification.

@nl

type

Item

label

Industry Perspective on Biomarker Development and Qualification.

@en

Industry Perspective on Biomarker Development and Qualification.

@nl

prefLabel

Industry Perspective on Biomarker Development and Qualification.

@en

Industry Perspective on Biomarker Development and Qualification.

@nl

P1476

Industry Perspective on Biomarker Development and Qualification.

@en

P2093

Cory V Gerlach

http://www.w3.org/2001/XMLSchema#string

Mazin Derzi

http://www.w3.org/2001/XMLSchema#string

Shashi K Ramaiah

http://www.w3.org/2001/XMLSchema#string

Vishal S Vaidya

http://www.w3.org/2001/XMLSchema#string

P2860

Adaptive Biomedical Innovation: Evolving Our Global System to Sustainably and Safely Bring New Medicines to Patients in Need.

An analysis of the attrition of drug candidates from four major pharmaceutical companies.

Industry perspectives on biomarker qualification.

Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization.

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.

Approving a Problematic Muscular Dystrophy Drug: Implications for FDA Policy.

Kidney injury molecule-1 (KIM-1), a putative epithelial cell adhesion molecule containing a novel immunoglobulin domain, is up-regulated in renal cells after injury.

New "21st Century Cures" Legislation: Speed and Ease vs Science.

P304

27-31

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/CPT.919

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29143971

http://www.w3.org/2001/XMLSchema#string

Industry Perspective on Biomarker Development and Qualification.

about

P2860

P2860

Industry Perspective on Biomarker Development and Qualification.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698